ReviewMolecular biology reports2026
GATA binding protein 4: Emerging role in liver development and diseases.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
GATA binding protein 4 (GATA4) is a zinc finger DNA binding protein first identified in 1993. As a pioneer transcription factor, GATA4 is indispensable for embryonic development, particularly liver development, and its abnormal expression has been associated with various diseases. In this review, we systematically summarize the current understanding of the embryological and physiological roles of GATA4 in the liver. Furthermore, we specifically focus on its regulatory functions in a broad spectrum of liver diseases, including metabolic dysfunction-associated steatotic liver disease, liver fibrosis, cirrhosis, hepatocellular carcinoma and other conditions such as viral hepatitis, hepatic encephalopathy and iron metabolism disorder. Ultimately, the potential and obstacle of GATA4 as a therapeutic target for liver diseases has been discussed. Although further investigation is warranted, GATA4 holds potential as a future therapeutic target for liver diseases in the context of precision medicine.
Indexed as
Identifiers
42397614What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.